90Y-Besilesomab is the therapeutic analogue of the 99mTc-labeled murine anti-granulocyte mAb BW250/183 available under the trade name Scintimun®. This molecule is developed as a therapeutic agent for the treatment of systemic amyloid light chain amyloidosis (SALA) using the companion diagnostic agent 111In-Besilesomab. 90Y-besilesomab has been granted orphan drug designation status in Europe for the broad indication of Bone Marrow Conditioning (BMC) for Hematopoietic Stem Cell Transplantation (HSCT).

The antibody is targeting CD66 and the 90Y-labeled form is now evaluated in patients affected by amyloidosis on the basis of a SPECT confirmation of the presence of the disease with the 111In-analogue.

Target/Mechanism: CD66

Leading Emitter: beta electrons (β)